These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31180073)

  • 21. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.
    De Preter V; Machiels K; Joossens M; Arijs I; Matthys C; Vermeire S; Rutgeerts P; Verbeke K
    Gut; 2015 Mar; 64(3):447-58. PubMed ID: 24811995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
    Lee T; Clavel T; Smirnov K; Schmidt A; Lagkouvardos I; Walker A; Lucio M; Michalke B; Schmitt-Kopplin P; Fedorak R; Haller D
    Gut; 2017 May; 66(5):863-871. PubMed ID: 26848182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low counts of Faecalibacterium prausnitzii in colitis microbiota.
    Sokol H; Seksik P; Furet JP; Firmesse O; Nion-Larmurier I; Beaugerie L; Cosnes J; Corthier G; Marteau P; Doré J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1183-9. PubMed ID: 19235886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity.
    Oldenburg B; van Kats-Renaud H; Koningsberger JC; van Berge Henegouwen GP; van Asbeck BS
    Clin Chim Acta; 2001 Aug; 310(2):151-6. PubMed ID: 11498080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
    Machiels K; Joossens M; Sabino J; De Preter V; Arijs I; Eeckhaut V; Ballet V; Claes K; Van Immerseel F; Verbeke K; Ferrante M; Verhaegen J; Rutgeerts P; Vermeire S
    Gut; 2014 Aug; 63(8):1275-83. PubMed ID: 24021287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.
    Hu X; Deng J; Yu T; Chen S; Ge Y; Zhou Z; Guo Y; Ying H; Zhai Q; Chen Y; Yuan F; Niu Y; Shu W; Chen H; Ma C; Liu Z; Guo F
    Gastroenterology; 2019 Mar; 156(4):1098-1111. PubMed ID: 30452920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis.
    Fahlgren A; Hammarström S; Danielsson A; Hammarström ML
    Clin Exp Immunol; 2003 Jan; 131(1):90-101. PubMed ID: 12519391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease.
    Zhang W; Teng G; Wu T; Tian Y; Wang H
    Inflamm Bowel Dis; 2017 Dec; 23(12):2134-2141. PubMed ID: 29084078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Horizontal distribution of the fecal microbiota in adolescents with inflammatory bowel disease.
    Gosiewski T; Strus M; Fyderek K; Kowalska-Duplaga K; Wedrychowicz A; Jedynak-Wasowicz U; Sladek M; Pieczarkowski S; Adamski P; Heczko PB
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):20-7. PubMed ID: 21788912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.
    Schaefer JS; Attumi T; Opekun AR; Abraham B; Hou J; Shelby H; Graham DY; Streckfus C; Klein JR
    BMC Immunol; 2015 Feb; 16():5. PubMed ID: 25886994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease.
    Davenport M; Poles J; Leung JM; Wolff MJ; Abidi WM; Ullman T; Mayer L; Cho I; Loke P
    Inflamm Bowel Dis; 2014 Apr; 20(4):723-31. PubMed ID: 24583479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.
    Furrie E; Macfarlane S; Cummings JH; Macfarlane GT
    Gut; 2004 Jan; 53(1):91-8. PubMed ID: 14684582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
    Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
    J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis.
    Alipour M; Zaidi D; Valcheva R; Jovel J; Martínez I; Sergi C; Walter J; Mason AL; Wong GK; Dieleman LA; Carroll MW; Huynh HQ; Wine E
    J Crohns Colitis; 2016 Apr; 10(4):462-71. PubMed ID: 26660940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fungi and inflammatory bowel diseases: Alterations of composition and diversity.
    Ott SJ; Kühbacher T; Musfeldt M; Rosenstiel P; Hellmig S; Rehman A; Drews O; Weichert W; Timmis KN; Schreiber S
    Scand J Gastroenterol; 2008; 43(7):831-41. PubMed ID: 18584522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.
    Oriishi T; Sata M; Toyonaga A; Sasaki E; Tanikawa K
    Gut; 1995 Jun; 36(6):891-6. PubMed ID: 7615279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease.
    Peyrin-Biroulet L; Gonzalez F; Dubuquoy L; Rousseaux C; Dubuquoy C; Decourcelle C; Saudemont A; Tachon M; Béclin E; Odou MF; Neut C; Colombel JF; Desreumaux P
    Gut; 2012 Jan; 61(1):78-85. PubMed ID: 21940721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paraoxonase-1 status in Crohn's disease and ulcerative colitis.
    Boehm D; Krzystek-Korpacka M; Neubauer K; Matusiewicz M; Berdowska I; Zielinski B; Paradowski L; Gamian A
    Inflamm Bowel Dis; 2009 Jan; 15(1):93-9. PubMed ID: 18626964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.